<DOC>
	<DOCNO>NCT01289431</DOCNO>
	<brief_summary>The objective study evaluate dose response , efficacy Mapracorat ophthalmic formulation compare vehicle prevention symptom sign associate allergic conjunctivitis use conjunctival allergen challenge ( CAC ) model .</brief_summary>
	<brief_title>Mapracorat Ophthalmic Formulation Subjects With Allergic Conjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<criteria>positive history ocular allergy positive skin test reaction positive bilateral CAC reaction know contraindication sensitivity use study medication ( ) component . ocular condition significant illness , opinion investigator , could affect subject 's safety trial parameter . ocular surgical intervention within three ( 3 ) month prior Visit 1 study and/or history refractive surgery within past 3 month ; know history retinal detachment , diabetic retinopathy , active retinal disease ; presence active ocular infection positive history ocular herpetic infection visit . use disallow medication period indicate prior Visit 1 study . plan surgery trial period within 30 day . intraocular pressure le 5 mmHg great 22 mmHg type glaucoma Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>